Newsfile Corp
12 Oct 2026, 19:48 UTC · 1d ago
AARD DEADLINE TOMORROW: ROSEN, REGARDED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 13 Deadline in Securities Class Action - AARD
Impact · against what's priced in
The news is largely neutral for HIMS as the market already expects ongoing legal drag from class-action lawsuits. For Aardvark Therapeutics, the looming deadline for lead plaintiff selection increases the immediate visibility of serious safety allegations regarding its lead drug candidate, ARD-101.
- HIMS−0.05
Already priced in
- The price assumes
a clean resolution to the FTC and class-action lawsuits





